Background
A leading expert on brain injury, Daniel F. Hanley has been a professor of neurology, neurosurgery, and anesthesiology/critical care medicine at the Johns Hopkins University School of Medicine since 1996. In 1999, he founded the Division of Brain Injury Outcomes and was named the Jeffrey and Harriet Legum Chair of Acute Care Neurology. Dr. Hanley is a graduate of Williams College and Cornell University Medical College.
Dr. Hanley’s 35 years in medicine have centered on the areas of clinical trial design, organization and interpretation of drug and device trials, development of strategic research plans, and FDA regulatory compliance. He is the principal investigator for the NIH-sponsored MISTIE III and CLEAR III trials investigating minimally invasive neurosurgical techniques to treat hemorrhagic stroke. As principal investigator for the National Center for Advancing Translational Sciences (NCATS) Johns Hopkins-Tufts Trial Innovation Center, Dr. Hanley leads collaborative efforts to advance education and therapeutics via well-designed and innovative CTSA clinical trials.
Dr. Hanley has received more than 70 clinical and basic research grants, predominantly from the National Institutes of Health and the FDA Orphan Products Grants Program. He has published nearly 300 articles in peer-reviewed journals, has received the Alexander Humboldt Research Prize for his accomplishments in brain injury research, and has extensive clinical trials experience in the fields of stroke, hemorrhage, trauma, and brain infections. Of the nearly 100 researchers he has mentored, more than 40 have been named full professors, program leaders, or department chairs. His trainees lead brain intensive care units across the world. Dr. Hanley recently received the 2018 Distinguished Investigator Award from the American College of Critical Care Medicine.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.